Agreed

The COGNISION® System is also used by clinicians to evaluate patients suffering from Alzheimer's disease and concussion.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference. Christopher U Missling, PhD, President & Chief Executive Officer is scheduled to present at 1:30pm ET, TRACK 2 on Thursday, April 18th, 2024.

A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.

https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-noble-capital-markets-virtual-healthcare-equity-conference

4/18/24

Certainly a departure from the norm... hopefully know soon if positive.

Good to hear from you. Best to all and the twins.

Thank you for sharing! Best wishes for you sab!

Congratulations! Keep up that PT!!!

Agreed. Bodes well for avxl and delays.

https://www.neurologylive.com/view/fda-issues-revised-draft-guidance-drug-development-early-ad


The FDA's revised guidance aims to streamline drug development for early-stage AD by focusing on diagnostic criteria and outcome measures.
Surrogate endpoints, like biomarkers, are suggested for use in clinical trials to predict clinical benefit in patients with early AD.
Drug developers are encouraged to engage with the FDA early in the development process regarding the use of surrogate endpoints for AD treatment trials.

True

Yes, we could get lucky after all. (With more time, lol)

http://www.recentcare.com.tw/milestones_page?menuid=9


"Unfunded"
https://tracxn.com/d/companies/hidramed-solutions/__vZ4wZt8O7CnzIFAUGK591Z-5ZKgzrnWHz0lfWIPfmKA/competitors

Alrighty then. See what plays out now....

BHPA post-merger is now the business of Aquiva described supra.

The mission of Aquiva is to leverage its proprietary AQUIPHER(TM) technologies to facilitate the development and manufacturing of transdermal patches with larger varieties of active ingredients and to work with partners to bring these patches to the market.

Huge $$ in weight loss and seems to help with depression. Hmmm ol gut biome connection we have heard about in our pipeline

Thanks, interesting.

this theory will be tested soon and shall all see
"From here, we should begin to see short covering and more institutions starting to take/increase long positions. It's all by design."

More trial stats input:

https://ecommons.cornell.edu/items/d17a7470-70e5-4e55-bda3-8ff815aafc85

STATISTICAL ISSUES IN THE DESIGN AND ANALYSIS OF CLINICAL TRIALS
A Dissertation
Presented to the Faculty of the Graduate School
of Cornell University
In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy
by Yanning Liu Aug, 2016

Agreed. Hope now is a buyer of shell.

Thank you Xena

Interesting. Thanks

An vs down 10%. Others as well. Idk.

https://www.bbc.com/news/health-68126907.amp

Medicine stopped in 1980s linked to rare Alzheimer's cases

Correct

Proves Xena's point about similarities, see link she shared below: in addition to exposure in publication...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461987/

And now....

Psychiatric Times was established in 1985 as a psychiatric publication to provide mental health professionals with up-to-date news, research, and clinical information. The website curates content by and for mental health care professionals.

Psychiatric Times TM, a top psychiatric publication in the United States and the go-to resource for mental health care physicians and professionals, has provided timely clinical, commentary, and practical information.

Examination may include a few more questions (do you hurt anywhere else)with same end result of treatment of "a cast". Depending on answers, may justify additional imaging however, example is correct for dx provided.

Getting some traction...

https://www.psychiatrictimes.com/view/drug-candidate-for-schizophrenia-alzheimer-disease-approved-to-initiate-phase-2-trial-in-q2-2024

Damn good analogy. Thanks for info and link.

Agreed. Ignore button saves time and stress cutting the the noise, A Lot!!
GLTUA

Interesting. Dated today update. https://csimarket.com/news/anavex-life-sciences-unlocks-new-possibilities-in-neurodegenerative-disorder-treatment-groundbreaking-breakthroughs-in-c2024-01-24123428

https://financialpost.com/globe-newswire/bigg-digital-assets-subsidiary-netcoins-announces-q4-results-and-the-launch-of-netcoins-crypto-trading-api/wcm/11ca1e82-7d77-4153-9c99-d4683245caca/amp/

Agree

ThankYou! And the Rett Syndrome parents group is a small and unique group of parents that rely on each other for much needed support.
If "Alice" says her is daughter is better, I am happy for her and believe I see it in my child too. People desperate for good news "see" what they need to keep hope alive.

Dont we have confirmation bias experts here as well???

100k buy??? Thats some confidence

Would be nice!!

Over 91% of patients completing the trial continued into a 48-week open-label extension study (OLE), which is ongoing. Upon patient’s caregivers and investigators request, Anavex has established Compassionate Use Programs in Canada, Australia, and the UK for pediatric patients upon completion of the OLE study, similarly to its existing program for adult patients with Rett syndrome. To date, of the pediatric patients who completed the OLE, 93% have joined the Compassionate Use Program. This rate is comparable to the Compassionate Use level seen for adult patients which is over 96%. As of today, some patients with Rett syndrome have been on ANAVEX®2-73-treatment for over 4 years, combined OLE and Compassionate Use Program.

Or how many agreed to be filmed and speak on camera that were approached or volunteered?

BTC News 3 hours ago:
ARK Invest Pivots To Bitcoin As Cathie Wood Expects BTC Price To Explode

Source: NEWSBTC
CEO of ARK Invest, Cathie Wood has shared her perspective on the approval timeline for Spot Bitcoin ETFs. She has also highlighted the significant impact the official authorization of Bitcoin ETFs would have on the price of BTC. BTC Price Boom Predicted Following ETF Acceptance Founder and CEO of American asset investment management firm, ARK Invest, Catherine Duddy Wood has recently appeared in an interview with Yahoo Finance. The live interview which was published via YouTube centers on Wood’s views and opinions regarding the potential approval of Spot Bitcoin ETFs and its effect on the price of BTC. Related Reading: Top Banker Reveals Why XRP Price Will Rise 390,000% To $2,500 According to the ARK Invest CEO, the price of BTC could surge substantially if the United States Securities and Exchange Commission (SEC) approves Spot Bitcoin ETFs for institutional investors. “What we think is going to happen here is that the SEC is going to be giving BTC, a spot bitcoin ETF, the green light for institutional investors to participate. I think a lot of institutions have been reticent before the SEC approves a spot bitcoin ETF to do very much at all in the crypto asset world,” Wood stated. She added: “All we need is for the trillions of dollars in institutional assets out there to allocate maybe 0.1% or 0.2% to an ETF, which will be one of the easiest ways to gain exposure and one of the most efficient ways to gain exposure to BTC. That will move the price significantly.” BTC price fails to beat resistance at $43,000 | Source: BTCUSD on Tradingview.com Bitcoin ETF Approval Expected In January During the interview, Wood outlined a timeline for the approval of Spot Bitcoin ETFs, predicting the potential approval dates for January. “We do think it will be in January. Famous last words, don’t want to say we know anything, because we don’t. But it’s just the actions of the SEC that are leading us to that conclusion,” Wood said. Related Reading: Dogecoin Whale Moves 71 Million DOGE To Robinhood, What Does This Mean For Price? Despite the positive forecast, the ARK Invest founder also stated that if the US SEC remains undecided about Spot Bitcoin ETFs, then a BTC ETF may not be necessary. “We don’t want a spot bitcoin ETF to get the green light if there are any uncertainties that the SEC may have. So I think we’re answering those uncertainties one by one, each of the filers for a spot bitcoin ETF. And I think the dialogues are very positive. I think the outlook is bright for a spot bitcoin ETF,” Wood stated. Featured image from Markets Insider, chart from Tradingview.com

Happy and Safe New Year to All
2024 will be Fun !

Yup. Btc is coming of age. Added.